{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:44:32Z","timestamp":1792547072671,"version":"4.5.0"},"reference-count":88,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T00:00:00Z","timestamp":1766102400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000738","name":"US Department of Veterans Affairs","doi-asserted-by":"publisher","award":["36C24519C0242"],"award-info":[{"award-number":["36C24519C0242"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","practicalradonc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Practical Radiation Oncology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.prro.2025.11.003","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T04:53:52Z","timestamp":1769057632000},"page":"294-317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Dose-Volume Histogram Compendium of Dose Constraints for Treatment Planning: An ASTRO Consensus Paper"],"prefix":"10.1016","volume":"16","author":[{"given":"Lindsay L.","family":"Puckett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Apisarnthanarax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie K.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhishamjit S.","family":"Chera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indrin J.","family":"Chetty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6362-8941","authenticated-orcid":false,"given":"Samantha L.","family":"Dawes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"DeMarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine E.","family":"Eyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karyn A.","family":"Goodman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustin","family":"Jacqmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Katsoulakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Ko","family":"Bang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ksenija","family":"Kujundzic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Pursley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Rosu-Bubulac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek A.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prro.2025.11.003_bib0001","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","article-title":"Tolerance of normal tissue to therapeutic irradiation","volume":"21","author":"Emami","year":"1991","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3 suppl","key":"10.1016\/j.prro.2025.11.003_bib0002","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.ijrobp.2009.07.1754","article-title":"Use of normal tissue complication probability models in the clinic","volume":"76","author":"Marks","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0003","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1118\/1.3438081","article-title":"Stereotactic body radiation therapy: the report of AAPM Task Group 101","volume":"37","author":"Benedict","year":"2010","journal-title":"Med Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijrobp.2020.10.039","article-title":"High dose per fraction, hypofractionated treatment effects in the clinic (HyTEC): an overview","volume":"110","author":"Grimm","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.ijrobp.2021.09.027","article-title":"A story of hypofractionation and the table on the wall","volume":"112","author":"Timmerman","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0006","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.prro.2022.05.009","volume":"12","author":"Katsoulakis","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0007","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.prro.2022.05.005","article-title":"Consensus quality measures and dose constraints for rectal cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology (ASTRO) Expert Panel","volume":"12","author":"Park","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0008","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.prro.2022.08.016","article-title":"Consensus quality measures and dose constraints for breast cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel","volume":"13","author":"Puckett","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0009","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.prro.2023.04.003","article-title":"Consensus quality measures and dose constraints for lung cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and ASTRO Expert Panel","volume":"13","author":"Puckett","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0010","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/j.prro.2022.08.018","article-title":"Consensus quality measures and dose constraints for prostate cancer from the Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology Expert Panel","volume":"13","author":"Solanki","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0011","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2017.12.013","article-title":"American Association of Physicists in Medicine Task Group 263: standardizing nomenclatures in radiation oncology","volume":"100","author":"Mayo","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0012","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ijrobp.2017.01.204","article-title":"Application of critical volume-dose constraints for stereotactic body radiation therapy in NRG radiation therapy trials","volume":"98","author":"Ritter","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0013","doi-asserted-by":"crossref","first-page":"e117","DOI":"10.1016\/j.prro.2015.11.001","article-title":"Establishment of practice standards in nomenclature and prescription to enable construction of software and databases for knowledge-based practice review","volume":"6","author":"Mayo","year":"2016","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0014","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.ijrobp.2019.08.064","article-title":"VA-Radiation Oncology Quality Surveillance Program","volume":"106","author":"Hagan","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0015","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.prro.2022.05.015","article-title":"Veterans Affairs Radiation Oncology Quality Surveillance Program and American Society for Radiation Oncology quality measures initiative","volume":"12","author":"Park","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0016","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.prro.2018.12.003","article-title":"Standardizing normal tissue contouring for radiation therapy treatment planning: an ASTRO consensus paper","volume":"9","author":"Wright","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0017","doi-asserted-by":"crossref","first-page":"6303","DOI":"10.1002\/mp.15916","article-title":"Assessment of dose-volume histogram precision for five clinical systems","volume":"49","author":"Pepin","year":"2022","journal-title":"Med Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0018","unstructured":"National Cancer Institute. NSABP B-51\/RTOG 1304 protocol: A randomized phase III clinical trial evaluating post-mastectomy chestwall and regional nodal XRT and post-lumpectomy regional nodal XRT in patients with positive axillary nodes before neoadjuvant chemotherapy who convert to pathologically negative axillary nodes after neoadjuvant chemotherapy. Updated February 24, 2016. Accessed March 20, 2025. https:\/\/med.uc.edu\/docs\/default-source\/cancercenter\/all-protocols\/breast\/nsabp_b51_randomized-phase-iii-clinical-trial-evaluating-post-mastectomy-chestwall.pdf"},{"issue":"2 suppl","key":"10.1016\/j.prro.2025.11.003_bib0019","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/j.ijrobp.2024.07.002","article-title":"A randomized trial of hypofractionated post-mastectomy radiation therapy (PMRT) in women with breast reconstruction (RT CHARM, Alliance A221505) [abstract]","volume":"120","author":"Poppe","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16 suppl","key":"10.1016\/j.prro.2025.11.003_bib0020","doi-asserted-by":"crossref","first-page":"TPS613","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS613","article-title":"NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS \u226418 breast cancer [abstract]","volume":"40","author":"White","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0021","unstructured":"NRG Oncology. RTOG 1005 protocol: A phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer. Updated December 16, 2021. Accessed March 20, 2025. https:\/\/cdn.clinicaltrials.gov\/large-docs\/22\/NCT01349322\/Prot_SAP_000.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0022","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.prro.2018.01.012","article-title":"Radiation therapy for the whole breast: executive summary of an American Society for Radiation Oncology (ASTRO) evidence-based guideline","volume":"8","author":"Smith","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0023","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.prro.2023.11.001","article-title":"Partial breast irradiation for patients with early-stage invasive breast cancer or ductal carcinoma in situ: an ASTRO clinical practice guideline","volume":"14","author":"Shaitelman","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0024","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.prro.2025.11.003_bib0025","unstructured":"NRG Oncology. NRG-HN001 protocol: Randomized phase II and phase III studies of individualized treatment for nasopharyngeal carcinoma based on biomarker Epstein Barr virus (EBV) deoxyribonucleic acid (DNA). Updated October 23, 2017. Accessed March 18, 2025. https:\/\/med.uc.edu\/docs\/default-source\/cancercenter\/all-protocols\/head-and-neck\/nrg-hn001_protocol-(1).pdf?sfvrsn=cd608014_6"},{"key":"10.1016\/j.prro.2025.11.003_bib0026","unstructured":"NRG Oncology. NRG-HN009: Comparing two cisplatin dosing schedules combined with radiation for patients with advanced head and neck cancer. Accessed March 18, 2025. https:\/\/www.nrgoncology.org\/HN009"},{"key":"10.1016\/j.prro.2025.11.003_bib0027","unstructured":"NRG Oncology. NRG-HN003: A phase I and expansion cohort study of adjuvant cisplatin, intensity-modulated radiotherapy, and MK-3475 (pembrolizumab) in high-risk head and neck squamous cell carcinoma (HNSCC). Accessed March 18, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-hn003?filter=nrg-hn003"},{"key":"10.1016\/j.prro.2025.11.003_bib0028","unstructured":"NRG Oncology. RTOG 1016: Phase III trial of radiotherapy plus cetuximab versus chemoradiotherapy in HPV-associated oropharynx cancer. Updated February 23, 2016. Accessed March 18, 2025. https:\/\/cdn.clinicaltrials.gov\/large-docs\/34\/NCT01302834\/Prot_SAP_001.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0029","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.prro.2024.05.007","article-title":"Radiation therapy for HPV-positive oropharyngeal squamous cell carcinoma: an ASTRO clinical practice guideline","volume":"14","author":"Margalit","year":"2024","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0030","unstructured":"NRG Oncology. NRG-0619: A randomized phase II trial of chemoradiotherapy versus chemoradiotherapy and vandetanib for high-risk postoperative advanced squamous cell carcinoma of the head and neck. https:\/\/www.rtog.org\/Clinical-Trials\/Legacy-Studies. Accessed March 18, 2025."},{"key":"10.1016\/j.prro.2025.11.003_bib0031","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.ijrobp.2009.04.061","article-title":"Simple carotid-sparing intensity-modulated radiotherapy technique and preliminary experience for T1-2 glottic cancer","volume":"77","author":"Rosenthal","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0032","article-title":"Dose-volume-related dysphagia after constrictor muscles definition in head and neck cancer intensity-modulated radiation treatment","volume":"87","author":"Mazzola","year":"2014","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.11.003_bib0033","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.prro.2021.09.004","article-title":"External beam radiation therapy for primary liver cancers: an ASTRO clinical practice guideline","volume":"12","author":"Apisarnthanarax","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0034","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.ijrobp.2010.03.020","article-title":"Chest wall toxicity after stereotactic body radiotherapy for malignant lesions of the lung and liver","volume":"80","author":"Andolino","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0035","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ijrobp.2009.02.027","article-title":"Chest wall volume receiving >30 Gy predicts risk of severe pain and\/or rib fracture after lung stereotactic body radiotherapy","volume":"76","author":"Dunlap","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0036","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jama.2010.261","article-title":"Stereotactic body radiation therapy for inoperable early stage lung cancer","volume":"303","author":"Timmerman","year":"2010","journal-title":"JAMA"},{"key":"10.1016\/j.prro.2025.11.003_bib0037","unstructured":"NRG Oncology. RTOG 1112: Randomized phase III study of sorafenib versus stereotactic body radiation therapy followed by sorafenib in hepatocellular carcinoma. Published 2022. Accessed February 24, 2025. https:\/\/cdn.clinicaltrials.gov\/large-docs\/37\/NCT01730937\/ICF_001.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0038","unstructured":"NRG Oncology. NRG-GI003: A phase III randomized trial of protons versus photons for hepatocellular carcinoma. Accessed February 24, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gi003?filter=nrg-gi003"},{"key":"10.1016\/j.prro.2025.11.003_bib0039","unstructured":"SWOG Cancer Research Network. S1914: A randomized phase III trial of induction\/consolidation atezolizumab (NSC #783608) + SBRT versus SBRT alone in high risk, early stage NSCLC. Accessed March 18, 2025. https:\/\/www.swog.org\/clinical-trials\/s1914"},{"key":"10.1016\/j.prro.2025.11.003_bib0040","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.ijrobp.2011.03.053","article-title":"Dose-volume parameters predict for the development of chest wall pain after stereotactic body radiation for lung cancer","volume":"82","author":"Mutter","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0041","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.prro.2017.12.007","article-title":"Chest wall toxicity after hypofractionated proton beam therapy for liver malignancies","volume":"8","author":"Yeung","year":"2018","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0042","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.prro.2016.05.009","article-title":"Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions","volume":"7","author":"Swanick","year":"2017","journal-title":"Pract Radiat Oncol"},{"issue":"2 suppl","key":"10.1016\/j.prro.2025.11.003_bib0043","doi-asserted-by":"crossref","first-page":"E63","DOI":"10.1016\/j.ijrobp.2024.07.1917","article-title":"NRG LU008: Phase III prospective randomized trial of primary lung tumor stereotactic body radiation therapy (SBRT) followed by concurrent mediastinal chemoradiation for locally-advanced non-small cell lung cancer (LA-NSCLC). [abstract]","volume":"120","author":"Simone","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0044","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13014-016-0640-8","article-title":"Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC","volume":"11","author":"Giaddui","year":"2016","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0045","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer. Published 2025. Updated January 14, 2025. Accessed March 24, 2025. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0046","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.ijrobp.2013.07.029","article-title":"Predicting esophagitis after chemoradiation therapy for non-small cell lung cancer: an individual patient data meta-analysis","volume":"87","author":"Palma","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0047","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1200\/JCO.19.01162","article-title":"Long-term results of NRG Oncology RTOG 0617: Standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer","volume":"38","author":"Bradley","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0048","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.ijrobp.2007.03.011","article-title":"Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma","volume":"69","author":"Rice","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"16 suppl","key":"10.1016\/j.prro.2025.11.003_bib0049","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2022.40.16_suppl.8513","article-title":"Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1\u2013high locally advanced non-small cell lung cancer [abstract]","volume":"40","author":"Lin","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0050","doi-asserted-by":"crossref","first-page":"e187","DOI":"10.1016\/j.prro.2018.11.011","article-title":"Effect of tumor location and dosimetric predictors for chest wall toxicity in single-fraction stereotactic body radiation therapy for stage I non-small cell lung cancer","volume":"9","author":"Manyam","year":"2019","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0051","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1016\/j.ijrobp.2018.11.051","article-title":"Long-term follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer","volume":"103","author":"Videtic","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0052","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20170196","article-title":"A dosimetric parameter to limit chest wall toxicity in SABR of NSCLC","volume":"90","author":"Jumeau","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.prro.2025.11.003_bib0053","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/jamaoncol.2024.3089","article-title":"Stereotactic vs hypofractionated radiotherapy for inoperable stage I non-small cell lung cancer: the LUSTRE phase 3 randomized clinical trial","volume":"10","author":"Swaminath","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0054","doi-asserted-by":"crossref","first-page":"e529","DOI":"10.1016\/j.cllc.2018.04.001","article-title":"SUNSET: stereotactic radiation for ultracentral non-small-cell lung cancer\u2014a safety and efficacy trial","volume":"19","author":"Giuliani","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.prro.2025.11.003_bib0055","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.18.00622","article-title":"Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer: NRG Oncology\/RTOG 0813 trial","volume":"37","author":"Bezjak","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0056","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13014-020-01491-w","article-title":"Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumors","volume":"15","author":"Zhao","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0057","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.radonc.2014.07.010","article-title":"Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications","volume":"112","author":"Li","year":"2014","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0058","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/JTO.0000000000000453","article-title":"Stereotactic ablative radiotherapy for centrally located early stage non-small-cell lung cancer: what we have learned","volume":"10","author":"Chang","year":"2015","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0059","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.prro.2023.01.005","article-title":"ASTRO radiation therapy summary of the ASCO guideline on management of stage III non-small cell lung cancer","volume":"13","author":"Simone","year":"2023","journal-title":"Pract Radiat Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0060","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1200\/JCO.23.02445","article-title":"Long-term analysis of NRG Oncology RTOG 0415: A randomized phase III noninferiority study comparing two fractionation schedules in patients with low-risk prostate cancer","volume":"42","author":"Lee","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0061","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG Oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0062","unstructured":"Radiation Therapy Oncology Group. RTOG 0924 protocol: Androgen deprivation therapy and high dose radiotherapy with or without whole-pelvic randomized trial radiotherapy in unfavorable intermediate or favorable high risk prostate cancer: a phase III. Updated June 16, 2011. Accessed March 24, 2025. https:\/\/irochouston.mdanderson.org\/rpc\/credentialing\/files\/0924.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0063","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1200\/JCO.22.02390","article-title":"Dose-escalated radiotherapy alone or in combination with short-term androgen deprivation for intermediate-risk prostate cancer: results of a phase III multi-institutional trial","volume":"41","author":"Krauss","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0064","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0065","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG Oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0066","unstructured":"Radiation Therapy Oncology Group. RTOG 0534 protocol: A phase III trial of short term androgen deprivation with pelvic lymph node or prostate bed only radiotherapy (SPPORT) in protstate cancer patients with a rising PSA after radical prostatectomy. Updated December 23, 2010. Accessed March 24, 2025. https:\/\/irochouston.mdanderson.org\/rpc\/credentialing\/files\/0534.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0067","unstructured":"NRG Oncology. NRG-GU010: Parallel phase III randomized trials of genomic-risk stratified unfavorable intermediate risk prostate cancer: de-intensification and intensification clinical trial evaluation (GUIDANCE). Accessed March 24, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gu010?filter=nrg-gu010"},{"key":"10.1016\/j.prro.2025.11.003_bib0068","unstructured":"NRG Oncology. NRG-GU013: The phase III \u2018High Five Trial\u2019 five fraction radiation for high-risk prostate cancer.https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gu013?filter=nrg-gu013. Accessed March 24, 2024."},{"key":"10.1016\/j.prro.2025.11.003_bib0069","unstructured":"NRG Oncology. NRG-GU009: The PREDICT-RT Trial: Testing hormone therapy treatment to improve outcomes for men with high-risk prostate cancer categorized by low or high gene risk score. Accessed March 24, 2025. https:\/\/www.nrgoncology.org\/PREDICT-RT"},{"key":"10.1016\/j.prro.2025.11.003_bib0070","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2020.01.003","article-title":"Derivation of dose\/volume constraints for the anorectum from clinician- and patient-reported outcomes in the CHHiP trial of radiation therapy fractionation","volume":"106","author":"Wilkins","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0071","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.ijrobp.2016.11.038","article-title":"Six questions to ask before we shorten radiation treatments for intact prostate cancer","volume":"97","author":"Bekelman","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0072","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of hypofractionated vs conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: the NRG-GU003 phase 3 randomized clinical trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"issue":"6 suppl","key":"10.1016\/j.prro.2025.11.003_bib0073","doi-asserted-by":"crossref","first-page":"TPS179","DOI":"10.1200\/JCO.2021.39.6_suppl.TPS179","article-title":"INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with\/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy","volume":"39","author":"Chen","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0074","unstructured":"NRG Oncology. NRG-GU005: Phase III IGRT and SBRT versus IGRT and hypofractionated IMRT for localized intermediate risk prostate cancer. Accessed March 24, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/nrg-gu005?filter=nrg-gu005"},{"key":"10.1016\/j.prro.2025.11.003_bib0075","unstructured":"Radiation Therapy Oncology Group. RTOG 0938: A randomized phase II trial of hypofractionated radiotherapy for favorable risk prostate cancer-RTOG CCOP study. Accessed March 24, 2025. https:\/\/www.nrgoncology.org\/Clinical-Trials\/Protocol\/rtog-0938?filter=rtog-0938"},{"key":"10.1016\/j.prro.2025.11.003_bib0076","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2403365","article-title":"Phase 3 trial of stereotactic body radiotherapy in localized prostate cancer","volume":"391","author":"van As","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.11.003_bib0077","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0078","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0079","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0080","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.3390\/jpm12091442","article-title":"Assessment of radiation-induced bladder and bowel cancer risks after conventionally and hypo-fractionated radiotherapy for the preoperative management of rectal carcinoma","volume":"12","author":"Matsali","year":"2022","journal-title":"J Pers Med"},{"key":"10.1016\/j.prro.2025.11.003_bib0081","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1001\/jamaoncol.2021.1683","article-title":"Use of total neoadjuvant therapy for locally advanced rectal cancer: initial results from the pembrolizumab arm of a phase 2 randomized clinical trial","volume":"7","author":"Rahma","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0082","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa2303269","article-title":"Preoperative treatment of locally advanced rectal cancer","volume":"389","author":"Schrag","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.prro.2025.11.003_bib0083","unstructured":"Radiation Therapy Oncology Group. RTOG 0822: A phase II evaluation of preopartive chemoradiotherapy utilizing intensity modulated radiation therapy (IMRT) in combination with capecitabine and oxaliplatin for patients with locally advanced rectal cancer. Updated April 17, 2008. Accessed March 17, 2025. https:\/\/irochouston.mdanderson.org\/RPC\/credentialing\/files\/0822.pdf"},{"key":"10.1016\/j.prro.2025.11.003_bib0084","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1186\/s12885-024-12529-7","volume":"24","author":"Alvarez","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prro.2025.11.003_bib0085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.rpor.2014.06.003","article-title":"Could preoperative short-course radiotherapy be the treatment of choice for localized advanced rectal carcinoma?","volume":"20","author":"Ciria","year":"2015","journal-title":"Rep Pract Oncol Radiother"},{"issue":"16 suppl","key":"10.1016\/j.prro.2025.11.003_bib0086","doi-asserted-by":"crossref","first-page":"TPS3644","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS3644","article-title":"EA2201: An ECOG-ACRIN phase II study of neoadjuvant nivolumab plus ipilimumab and short course radiation in MSI-H\/dMMR rectal tumors [abstract]","volume":"40","author":"Ciombor","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.prro.2025.11.003_bib0087","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.ijrobp.2013.12.028","article-title":"Five fractions of radiation therapy followed by 4 cycles of FOLFOX chemotherapy as preoperative treatment for rectal cancer","volume":"88","author":"Myerson","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.prro.2025.11.003_bib0088","unstructured":"Gay HAB, Barthold HJ, O\u2019Meara E et al. Male pelvis normal tissue RTOG consensus contouring guidelines. Accessed February 19, 2025. https:\/\/nrgoncology.org\/wp-content\/uploads\/2025\/09\/Male-RTOG-Normal-Pelvis-Atlas.pdf"}],"container-title":["Practical Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025003054?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1879850025003054?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T10:33:44Z","timestamp":1778063624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1879850025003054"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":88,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1879850025003054"],"URL":"https:\/\/doi.org\/10.1016\/j.prro.2025.11.003","relation":{},"ISSN":["1879-8500"],"issn-type":[{"value":"1879-8500","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-Volume Histogram Compendium of Dose Constraints for Treatment Planning: An ASTRO Consensus Paper","name":"articletitle","label":"Article Title"},{"value":"Practical Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prro.2025.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.","name":"copyright","label":"Copyright"}]}}